FUNDAMENTALS · Fundamentals · AU Healthcare

Alterity Therapeutics (ATH) Fundamentals 2026 — Revenue Analysis | SniperIQ

Alterity Therapeutics (ATH) is a AU-listed Healthcare company in Biotechnology with a market capitalization of A

23M, trading at A$0.56 on the ASX. This SniperIQ fundamentals page covers Alterity Therapeutics's valuation, profitability (net margin -380.7%), revenue (A$5M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapA
23M
Net Margin-380.7%
Revenue (FY25)A$5M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Alterity Therapeutics's market cap?

Alterity Therapeutics (ATH) has a market capitalization of approximately A

23M, trading at A$0.56 on the ASX. Market cap moves with the live share price.

What is Alterity Therapeutics's P/E ratio?

Alterity Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Alterity Therapeutics?

Alterity Therapeutics runs a net profit margin of -380.7%, a gross margin of 96.8%, and an operating margin of -525.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Alterity Therapeutics generate?

Alterity Therapeutics reported revenue of A$5M for fiscal year 2025, with net income of -A

2M and earnings per share (EPS) of -0.095. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Alterity Therapeutics pay a dividend?

Alterity Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Alterity Therapeutics financially healthy?

Alterity Therapeutics carries a debt-to-equity ratio of 0.00x and a current ratio of 21.98x, with a market beta of -0.03. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Alterity Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Alterity Therapeutics (ATH) the key facts are: market cap A

23M, revenue A$5M, 52-week range 0.35-0.875. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Alterity Therapeutics's full fundamentals live

Get Alterity Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: OptimizeRx (OPRX) fundamentals · Alpha Cognition (ACOG) fundamentals · Alcidion Group (ALC) fundamentals · Anixa Biosciences (ANIX) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons